The risk of cardiometabolic disorders in lean non-alcoholic fatty liver disease: A longitudinal study
Background: Recent studies suggest that non-alcoholic fatty liver disease (NAFLD) in lean (BMI<25 kg/m2) individuals presents a distinct phenotype. We sought to determine the cardiometabolic consequences of lean NAFLD in a population cohort of relatively young asymptomatic individuals who partic...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-12-01
|
| Series: | American Journal of Preventive Cardiology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666667720300970 |
| _version_ | 1818565740329959424 |
|---|---|
| author | Ehimen C. Aneni Marcio Sommer Bittencourt Catherine Teng Miguel Cainzos-Achirica Chukwuemeka U. Osondu Ahmed Soliman Mouaz Al-Mallah Matthew Buddoff Edison R. Parise Raul D. Santos Khurram Nasir |
| author_facet | Ehimen C. Aneni Marcio Sommer Bittencourt Catherine Teng Miguel Cainzos-Achirica Chukwuemeka U. Osondu Ahmed Soliman Mouaz Al-Mallah Matthew Buddoff Edison R. Parise Raul D. Santos Khurram Nasir |
| author_sort | Ehimen C. Aneni |
| collection | DOAJ |
| description | Background: Recent studies suggest that non-alcoholic fatty liver disease (NAFLD) in lean (BMI<25 kg/m2) individuals presents a distinct phenotype. We sought to determine the cardiometabolic consequences of lean NAFLD in a population cohort of relatively young asymptomatic individuals who participated in a voluntary routine health promotion evaluation in Brazil. Methods: We analyzed data in our population collected from 2004 to 2016. Medical and demographic history, anthropometric measures, and fasting blood samples were obtained. Participants had ultrasonography to assess for fatty liver. We defined NAFLD as fatty liver in individuals scoring below 8 on the alcohol use disorders identification test (AUDIT). We included data from 9137 individuals who had complete data at baseline and at follow-up. Results: The prevalence of lean NAFLD in our cohort was 3.8%. Over the median follow-up period of 2.4 years (range 0.5–9.9 years), lean individuals had 74% (HR: 1.74 (1.39–2.18)) and 67% (1.67 (1.29–2.15)) greater risk of developing elevated BP and elevated glucose, and nearly 3 times the risk of atherogenic dyslipidemia (HR: 2.98 (2.10–4.24)) compared to lean individuals without NAFLD. Lean NAFLD individuals also had higher risk of developing elevated glucose (HR: 1.37 (1.07–1.75)) and atherogenic dyslipidemia (1.46 (1.05–2.01)) compared to non-lean individuals without NAFLD. However, there was no significant difference in the risk of elevated BP, elevated glucose or atherogenic dyslipidemia between lean NAFLD and non-lean individuals with NAFLD in fully adjusted models. Conclusion: Lean NAFLD is not metabolically benign. Further cardiovascular risk stratification and appropriate preventive measures should be considered in lean individuals who present with NAFLD. |
| first_indexed | 2024-12-14T01:44:56Z |
| format | Article |
| id | doaj.art-c03a6f80b9aa44fcad7d27aa807306e9 |
| institution | Directory Open Access Journal |
| issn | 2666-6677 |
| language | English |
| last_indexed | 2024-12-14T01:44:56Z |
| publishDate | 2020-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | American Journal of Preventive Cardiology |
| spelling | doaj.art-c03a6f80b9aa44fcad7d27aa807306e92022-12-21T23:21:35ZengElsevierAmerican Journal of Preventive Cardiology2666-66772020-12-014100097The risk of cardiometabolic disorders in lean non-alcoholic fatty liver disease: A longitudinal studyEhimen C. Aneni0Marcio Sommer Bittencourt1Catherine Teng2Miguel Cainzos-Achirica3Chukwuemeka U. Osondu4Ahmed Soliman5Mouaz Al-Mallah6Matthew Buddoff7Edison R. Parise8Raul D. Santos9Khurram Nasir10Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA; Corresponding author.Center for Clinical and Epidemiological Research, University Hospital and State of São Paulo Cancer Institute (ICESP), University of São Paulo, São Paulo, Brazil; Hospital Israelita Albert Einstein, São Paulo, BrazilDepartment of Internal Medicine, Yale New Haven Health - Greenwich Hospital, Greenwich, CT, USAHouston Methodist, Debakey Heart and Vascular Institute, Houston, TX, USABaptist Health South Florida, Miami, FL, USAHouston Methodist, Debakey Heart and Vascular Institute, Houston, TX, USAHouston Methodist, Debakey Heart and Vascular Institute, Houston, TX, USADavid Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USAFederal University of Sao Paulo (UNIFESP), Sao Paulo, BrazilHospital Israelita Albert Einstein, São Paulo, Brazil; Lipid Clinic Heart Institute (InCor), University of São Paulo Medical School Hospital, São Paulo, BrazilHouston Methodist, Debakey Heart and Vascular Institute, Houston, TX, USABackground: Recent studies suggest that non-alcoholic fatty liver disease (NAFLD) in lean (BMI<25 kg/m2) individuals presents a distinct phenotype. We sought to determine the cardiometabolic consequences of lean NAFLD in a population cohort of relatively young asymptomatic individuals who participated in a voluntary routine health promotion evaluation in Brazil. Methods: We analyzed data in our population collected from 2004 to 2016. Medical and demographic history, anthropometric measures, and fasting blood samples were obtained. Participants had ultrasonography to assess for fatty liver. We defined NAFLD as fatty liver in individuals scoring below 8 on the alcohol use disorders identification test (AUDIT). We included data from 9137 individuals who had complete data at baseline and at follow-up. Results: The prevalence of lean NAFLD in our cohort was 3.8%. Over the median follow-up period of 2.4 years (range 0.5–9.9 years), lean individuals had 74% (HR: 1.74 (1.39–2.18)) and 67% (1.67 (1.29–2.15)) greater risk of developing elevated BP and elevated glucose, and nearly 3 times the risk of atherogenic dyslipidemia (HR: 2.98 (2.10–4.24)) compared to lean individuals without NAFLD. Lean NAFLD individuals also had higher risk of developing elevated glucose (HR: 1.37 (1.07–1.75)) and atherogenic dyslipidemia (1.46 (1.05–2.01)) compared to non-lean individuals without NAFLD. However, there was no significant difference in the risk of elevated BP, elevated glucose or atherogenic dyslipidemia between lean NAFLD and non-lean individuals with NAFLD in fully adjusted models. Conclusion: Lean NAFLD is not metabolically benign. Further cardiovascular risk stratification and appropriate preventive measures should be considered in lean individuals who present with NAFLD.http://www.sciencedirect.com/science/article/pii/S2666667720300970Non-alcoholic fatty liver diseaseCardiometabolic diseaseLean individualsInflammationTriglycerides |
| spellingShingle | Ehimen C. Aneni Marcio Sommer Bittencourt Catherine Teng Miguel Cainzos-Achirica Chukwuemeka U. Osondu Ahmed Soliman Mouaz Al-Mallah Matthew Buddoff Edison R. Parise Raul D. Santos Khurram Nasir The risk of cardiometabolic disorders in lean non-alcoholic fatty liver disease: A longitudinal study American Journal of Preventive Cardiology Non-alcoholic fatty liver disease Cardiometabolic disease Lean individuals Inflammation Triglycerides |
| title | The risk of cardiometabolic disorders in lean non-alcoholic fatty liver disease: A longitudinal study |
| title_full | The risk of cardiometabolic disorders in lean non-alcoholic fatty liver disease: A longitudinal study |
| title_fullStr | The risk of cardiometabolic disorders in lean non-alcoholic fatty liver disease: A longitudinal study |
| title_full_unstemmed | The risk of cardiometabolic disorders in lean non-alcoholic fatty liver disease: A longitudinal study |
| title_short | The risk of cardiometabolic disorders in lean non-alcoholic fatty liver disease: A longitudinal study |
| title_sort | risk of cardiometabolic disorders in lean non alcoholic fatty liver disease a longitudinal study |
| topic | Non-alcoholic fatty liver disease Cardiometabolic disease Lean individuals Inflammation Triglycerides |
| url | http://www.sciencedirect.com/science/article/pii/S2666667720300970 |
| work_keys_str_mv | AT ehimencaneni theriskofcardiometabolicdisordersinleannonalcoholicfattyliverdiseasealongitudinalstudy AT marciosommerbittencourt theriskofcardiometabolicdisordersinleannonalcoholicfattyliverdiseasealongitudinalstudy AT catherineteng theriskofcardiometabolicdisordersinleannonalcoholicfattyliverdiseasealongitudinalstudy AT miguelcainzosachirica theriskofcardiometabolicdisordersinleannonalcoholicfattyliverdiseasealongitudinalstudy AT chukwuemekauosondu theriskofcardiometabolicdisordersinleannonalcoholicfattyliverdiseasealongitudinalstudy AT ahmedsoliman theriskofcardiometabolicdisordersinleannonalcoholicfattyliverdiseasealongitudinalstudy AT mouazalmallah theriskofcardiometabolicdisordersinleannonalcoholicfattyliverdiseasealongitudinalstudy AT matthewbuddoff theriskofcardiometabolicdisordersinleannonalcoholicfattyliverdiseasealongitudinalstudy AT edisonrparise theriskofcardiometabolicdisordersinleannonalcoholicfattyliverdiseasealongitudinalstudy AT rauldsantos theriskofcardiometabolicdisordersinleannonalcoholicfattyliverdiseasealongitudinalstudy AT khurramnasir theriskofcardiometabolicdisordersinleannonalcoholicfattyliverdiseasealongitudinalstudy AT ehimencaneni riskofcardiometabolicdisordersinleannonalcoholicfattyliverdiseasealongitudinalstudy AT marciosommerbittencourt riskofcardiometabolicdisordersinleannonalcoholicfattyliverdiseasealongitudinalstudy AT catherineteng riskofcardiometabolicdisordersinleannonalcoholicfattyliverdiseasealongitudinalstudy AT miguelcainzosachirica riskofcardiometabolicdisordersinleannonalcoholicfattyliverdiseasealongitudinalstudy AT chukwuemekauosondu riskofcardiometabolicdisordersinleannonalcoholicfattyliverdiseasealongitudinalstudy AT ahmedsoliman riskofcardiometabolicdisordersinleannonalcoholicfattyliverdiseasealongitudinalstudy AT mouazalmallah riskofcardiometabolicdisordersinleannonalcoholicfattyliverdiseasealongitudinalstudy AT matthewbuddoff riskofcardiometabolicdisordersinleannonalcoholicfattyliverdiseasealongitudinalstudy AT edisonrparise riskofcardiometabolicdisordersinleannonalcoholicfattyliverdiseasealongitudinalstudy AT rauldsantos riskofcardiometabolicdisordersinleannonalcoholicfattyliverdiseasealongitudinalstudy AT khurramnasir riskofcardiometabolicdisordersinleannonalcoholicfattyliverdiseasealongitudinalstudy |